{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:21:23Z","timestamp":1784193683396,"version":"3.55.0"},"reference-count":56,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Melphalan-based percutaneous hepatic perfusion (M-PHP) became approved in 2023 for treatment of liver-dominant metastatic uveal melanoma (mUM). Patients with liver-dominant mUM have a poor overall survival (OS) \u2264 12 months; however, the reported OS benefit from M-PHP varies in clinical trials from 9.6 to 27.4 months and remains uncertain. Here, we report the OS outcome after 10 years\u2019 experience with M-PHP treatment of patients with liver-dominant mUM. Methods: A total of 38 consecutive patients (19 women, median age 57.7 years) with liver-dominant mUM underwent 99 M-PHP procedures (median: 2.6 M-PHP\/patient) between April 2014 and March 2024 at our institution. OS outcomes were retrospectively analyzed using Kaplan\u2013Meier methods and Cox proportional hazard models. Results: Median OS was 29.1 months after first M-PHP treatment (median follow-up: 25.8 months). The estimated percentage of patients surviving at 1, 2, and 3 years was 79.5%, 53.2%, and 28.5%, respectively. Each additional M-PHP cycle was associated with about 40% reduction in the risk of death (hazard ratio = 0.414). Median OS was numerically improved by 8.4 months with \u22653 versus \u22642 cycles of M-PHP administered (29.8 versus 21.4 months, p = 0.058). No treatment-related deaths occurred. Conclusions: This study found a clinically meaningful OS benefit in M-PHP-treated patients with liver-dominant mUM, reaching nearly 2.5-year median OS with \u22653 M-PHP cycles administered. This finding supports the need to account for the institutional volume and experience with the M-PHP procedure in both clinical practice and research, and may provide an OS reference for estimating OS gains in the evolving therapeutic landscape for mUM patients.<\/jats:p>","DOI":"10.3390\/cancers17233834","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T10:34:01Z","timestamp":1764758041000},"page":"3834","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Survival Outcome After Percutaneous Hepatic Perfusion with High-Dose Melphalan for Liver-Dominant Metastatic Uveal Melanoma: A 10-Year Single-Center Experience"],"prefix":"10.3390","volume":"17","author":[{"given":"Carolin M.","family":"Reiner","sequence":"first","affiliation":[{"name":"Asklepios Campus Hamburg, Semmelweis University, 20099 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Schneider","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Asklepios Hospital Barmbek, 22307 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hauke","family":"Weilert","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Palliative Care Medicine, Asklepios Hospital Barmbek, 22307 Hamburg, Germany"},{"name":"Asklepios Tumorzentrum, 22307 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klara","family":"Welcker","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Asklepios Hospital Barmbek, 22307 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Hoedtke","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care Medicine, Asklepios Hospital Barmbek, 22307 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8077-9306","authenticated-orcid":false,"given":"Andreas H.","family":"Mahnken","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology and Nuclear Medicine, St. Josef-Hospital, University Hospital, Ruhr University Bochum, 44791 Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8715-3349","authenticated-orcid":false,"given":"Axel","family":"Stang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Palliative Care Medicine, Asklepios Hospital Barmbek, 22307 Hamburg, Germany"},{"name":"Asklepios Tumorzentrum, 22307 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5737-7042","authenticated-orcid":false,"given":"Roland","family":"Br\u00fcning","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Asklepios Hospital Barmbek, 22307 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Wessely, A., Steeb, T., Erdmann, M., Heinzerling, L., Vera, J., Schlaak, M., Berking, C., and Heppt, M.V. (2020). The Role of Immune Checkpoint Blockade in Uveal Melanoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030879"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2217\/imt-2017-0066","article-title":"PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma","volume":"9","author":"Javed","year":"2017","journal-title":"Immunotherapy"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/s41588-019-0440-9","article-title":"The genetic evolution of metastatic uveal melanoma","volume":"51","author":"Shain","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Rodriguez, D.A., Sanchez, M.I., Decatur, C.L., Correa, Z.M., Martin, E.R., and Harbour, J.W. (2020). Impact of Genetic Ancestry on Prognostic Biomarkers in Uveal Melanoma. Cancers, 12.","DOI":"10.3390\/cancers12113208"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.semcancer.2020.05.003","article-title":"Uveal melanoma pathobiology: Metastasis to the liver","volume":"71","author":"Bustamante","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","article-title":"Advances in the clinical management of uveal melanoma","volume":"20","author":"Carvajal","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.ejso.2009.02.016","article-title":"Surgical management of liver metastases from uveal melanoma: 16 years\u2019 experience at the Institut Curie","volume":"35","author":"Mariani","year":"2009","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/CMR.0000000000000867","article-title":"Liver resection for metastatic uveal melanoma: Experience from a supra-regional centre and review of literature","volume":"33","author":"Trivedi","year":"2023","journal-title":"Melanoma Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1245\/s10434-025-17115-0","article-title":"Intention-to-Treat Analysis of Hepatic Resection for Liver Metastases from Uveal Melanoma: A Single-Center Experience","volume":"32","author":"Maspero","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/0284186X.2020.1817978","article-title":"Metastatic uveal melanoma managed with best supportive care","volume":"60","author":"Rantala","year":"2021","journal-title":"Acta Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: An international rare cancers initiative (IRCI) ocular melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","article-title":"Overall survival after treatment for metastatic uveal melanoma: A systematic review and meta-analysis","volume":"29","author":"Rantala","year":"2019","journal-title":"Melanoma Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.20.00550","article-title":"Nivolumab Plus Ipilimumab for Treatment-Na\u00efve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)","volume":"39","author":"Piulats","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.20.00605","article-title":"Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study","volume":"39","author":"Pelster","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7887","DOI":"10.1038\/s41598-024-55675-5","article-title":"Immune checkpoint inhibitors for metastatic uveal melanoma: A meta-analysis","volume":"14","author":"Yamada","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"17588359231198453","DOI":"10.1177\/17588359231198453","article-title":"Adverse events induced by durvalumab and tremelimumab combination regimens: A systematic review and meta-analysis","volume":"15","author":"Matsumoto","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"17588359211058393","DOI":"10.1177\/17588359211058393","article-title":"Adverse events induced by nivolumab and ipilimumab combination regimens","volume":"14","author":"Somekawa","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40123-024-00913-2","article-title":"The Future of Checkpoint Inhibitors in Uveal Melanoma: A Narrative Review","volume":"13","author":"Wang","year":"2024","journal-title":"Ophthalmol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.annonc.2023.11.013","article-title":"Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: A propensity score-weighted analysis","volume":"35","author":"Piulats","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/CMR.0000000000000919","article-title":"Cost-effectiveness analysis of an orphan drug tebentafusp in patients with metastatic uveal melanoma and a call for value-based pricing","volume":"33","author":"Luo","year":"2023","journal-title":"Melanoma Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"15330338251343144","DOI":"10.1177\/15330338251343144","article-title":"Percutaneous Locoregional Therapies for the Treatment of Liver Metastases from Uveal Melanoma: A Systematic Review","volume":"24","author":"Ini","year":"2025","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"104496","DOI":"10.1016\/j.esmoop.2025.104496","article-title":"How we treat patients with metastatic uveal melanoma","volume":"10","author":"Saldanha","year":"2025","journal-title":"ESMO Open"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ejso.2016.02.019","article-title":"Radiofrequency ablation and surgical resection of liver metastases from uveal melanoma","volume":"42","author":"Mariani","year":"2016","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jvir.2018.12.238","article-title":"03: 45 PM Abstract No. 184 Safety and efficacy of microwave ablation for uveal melanoma metastatic to the liver","volume":"30","author":"Sterbis","year":"2019","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2214\/AJR.14.14001","article-title":"Uveal Melanoma Metastatic to the Liver: Chemoembolization with 1,3-Bis-(2-Chloroethyl)-1-Nitrosourea","volume":"205","author":"Gonsalves","year":"2015","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1148\/radiol.2019190199","article-title":"A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis","volume":"293","author":"Gonsalves","year":"2019","journal-title":"Radiology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1245\/s10434-024-15293-x","article-title":"Efficacy and Safety of the Melphalan\/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study","volume":"31","author":"Zager","year":"2024","journal-title":"Ann. Surg. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1007\/s00270-017-1630-4","article-title":"Prospective Clinical and Pharmacological Evaluation of the Delcath System\u2019s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan","volume":"40","author":"Burgmans","year":"2017","journal-title":"Cardiovasc. Intervent Radiol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Kolb, M., Forschner, A., Artzner, C., Gr\u00f6zinger, G., Said, I., Dittmann, H., and Seith, F. (2023). Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for Metastasized Uveal Melanoma: A Retrospective Comparative Study. Cancers, 15.","DOI":"10.3390\/cancers15204942"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1245\/s10434-015-4968-3","article-title":"Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases","volume":"23","author":"Hughes","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/CMR.0000000000000806","article-title":"Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma","volume":"32","author":"Modi","year":"2022","journal-title":"Melanoma Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/jso.24956","article-title":"Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease","volume":"117","author":"Karydis","year":"2018","journal-title":"J. Surg. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Dewald, C.L.A., Warnke, M.M., Br\u00fcning, R., Schneider, M.A., Wohlmuth, P., Hinrichs, J.B., Saborowski, A., Vogel, A., and Wacker, F.K. (2021). Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience. Cancers, 14.","DOI":"10.3390\/cancers14010118"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1245\/s10434-020-08741-x","article-title":"Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study","volume":"28","author":"Meijer","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s00270-022-03225-9","article-title":"Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis","volume":"45","author":"Tong","year":"2022","journal-title":"Cardiovasc. Intervent Radiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40644-019-0218-4","article-title":"Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: A single center experience","volume":"19","author":"Artzner","year":"2019","journal-title":"Cancer Imaging"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s00270-017-1588-2","article-title":"Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study","volume":"40","author":"Vogl","year":"2017","journal-title":"Cardiovasc. Intervent Radiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1007\/s00330-018-5729-z","article-title":"Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival","volume":"29","author":"Marquardt","year":"2019","journal-title":"Eur. Radiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann. Surg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo classification of surgical complications: Five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann. Surg."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00270-017-1703-4","article-title":"Cirse Quality Assurance Document and Standards for Classification of Complications: The Cirse Classification System","volume":"40","author":"Filippiadis","year":"2017","journal-title":"Cardiovasc. Intervent Radiol."},{"key":"ref_46","unstructured":"Cox, D.R., and Oakes, D.O. (1984). Analysis of Survival Data, Chapman and Hall."},{"key":"ref_47","unstructured":"Kalbfleisch, J.D., and Prentice, R.L. (1980). The Statistical Analysis of Failure Time Data, Wiley."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1245\/s10434-025-17231-x","article-title":"An Open-label, Randomized Study of Melphalan\/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma","volume":"32","author":"Zager","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/SLA.0000000000006255","article-title":"Survival and Quality of Life After Isolated Hepatic Perfusion with Melphalan as a Treatment for Uveal Melanoma Liver Metastases: Final Results From the Phase III Randomized Controlled Trial SCANDIUM","volume":"282","author":"Nelson","year":"2025","journal-title":"Ann. Surg."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.3390\/cancers13184726","article-title":"Meta-Analysis of Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion as a Treatment for Uveal Melanoma Liver Metastases","volume":"13","author":"Bethlehem","year":"2021","journal-title":"Cancers"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"20210200","DOI":"10.1259\/bjr.20210200","article-title":"Selective internal radiation therapy for hepatic metastases of uveal melanoma: A systematic review","volume":"95","author":"Alexander","year":"2022","journal-title":"Br. J. Radiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13063-022-06036-y","article-title":"Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): Study protocol for a phase Ib\/randomized phase II trial","volume":"23","author":"Tong","year":"2022","journal-title":"Trials"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1232787","DOI":"10.3389\/fphar.2023.1232787","article-title":"Darovasertib, a novel treatment for metastatic uveal melanoma","volume":"14","author":"Cao","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40257-024-00872-1","article-title":"The Current State of Systemic Therapy of Metastatic Uveal Melanoma","volume":"25","author":"Koch","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"115161","DOI":"10.1016\/j.ejca.2024.115161","article-title":"Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11\/GNAQ mutant melanocytic tumors","volume":"214","author":"Dimitriou","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1038\/s41591-025-03650-6","article-title":"Autologous T cell therapy for PRAME(+) advanced solid tumors in HLA-A*02(+) patients: A phase 1 trial","volume":"31","author":"Wermke","year":"2025","journal-title":"Nat. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/23\/3834\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T10:49:02Z","timestamp":1764758942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/23\/3834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":56,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["cancers17233834"],"URL":"https:\/\/doi.org\/10.3390\/cancers17233834","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,29]]}}}